Welcome to GEMZAR.COM
Discovered and developed by scientists at Eli Lilly and Company, GEMZAR® (gemcitabine for injection) received its first FDA-approved indication in 1996. Today, GEMZAR has four indications:
- GEMZAR is approved by the FDA in combination with carboplatin (another type of chemotherapy)
for the patient with advanced ovarian cancer that has returned at least 6 months after the patient
had finished platinum-based therapy.
- GEMZAR is approved by the FDA in combination with cisplatin (another type of chemotherapy) for
the first-line treatment of patients (for whom surgery is not possible) with locally advanced (stage
IIIA or stage IIIB) or metastatic (stage IV or cancer that has spread) non-small cell lung cancer.
- GEMZAR is approved by the FDA in combination with paclitaxel for the first-line treatment of
patients with metastatic breast cancer after they have received another type of chemotherapy
called an anthracycline, unless their medical condition did not allow them to receive an
anthracycline.
- GEMZAR is approved by the FDA as a single agent (given alone) as the first-line treatment for
patients with locally advanced (stage II or stage III when surgery is not an option) or metastatic
(stage IV) adenocarcinoma of the pancreas. GEMZAR is also indicated for patients previously
treated with 5-FU (another type of chemotherapy).
GEMZAR can suppress bone marrow function, which may cause low blood cell counts.